PHG Newsletter 1/2018 – 7/2018

Dear members,

On behalf of the Public Health Genomics (PHG) Section, we bring you our latest Newsletter. Here you can find some interesting information from the Public Health Genomics field, space for networking, sharing ideas, and much more!

News From Our Section

We are proud to announce that the workshop ***"Personalised Healthcare: How is this relevant for advancing health in Europe?"*** organized by our Section will be held during the 11th EUPHA conference in Ljubljana on Friday 30th November from 16.20 to 17.50 h.

You will hear excellent presentations from international key-speakers. The workshop will be chaired by Dr. Natasha Azzopardi Muscat (President of EUPHA) and Prof. Paolo Villari (Sapienza University). We look forward to seeing you in Ljubljana and hope to generate some creative and dynamic discussions.

We are constantly striving to increase our visibility, enforce networking activities between our members and welcome new members to our PHG section. Therefore, you are very welcome to join us at the **Join the Network meeting** during the 11th EUPHA conference in Ljubljana. Details regarding our Join the Network meeting will be available soon.

Future events

EUPHA Conference 2018 "*Winds Of Change: Towards New Ways Of Improving Public Health In Europe*"
Cankarjev Dom, Ljubljana, Slovenia from 28 November - 1 December 2018

EUPHA 2018 Conference Programme is now available!

The Ljubljana conference programme (parallel sessions, workshops and poster walks) is made available on the EUPHA website (https://ephconference.eu/dynamic-programme-127)

Final conference of the PRECeDI project entitled "*Recommendations for Personalized Medicine: the contribution of PRECeDI in the field of prevention*" will be held in November 2018 in Brussels, Belgium. The contribution of the PRECeDI project in the field of personalised prevention as well as recommendations for personalized medicine will be one of the key topics on the agenda.
The conference will promote discussions among the speakers and the members of the audience regarding implementation processes, the impacts on health systems, collaboration between academic and industrial organisations, and perspectives of EU citizens and patients.
The event will feature lots of interesting speakers, including:
Stefania Boccia, UCSC, PRECeDI Coordinator
Cornelia Van Dujin, Erasmus MC, Netherlands
Paolo Villari, Sapienza University, Italy
Martina Cornel, VUMC, Netherlands
M'an Zawati, McGill
Ron Zimmern, PHG foundation
Natasha Azzopardi Muscat, EUPHA President

The European Alliance for Personalised Medicine (EAPM) is organizing the 2nd annual **Congress** entitled '*Forward as one: Integrating innovation into Europe's healthcare systems*' in Milan, Italy (26-28 November).

The Congress is dedicated to the fast-moving field of personalised medicine, with an emphasis on supporting Member States and regions in integrating innovation into healthcare systems. It will precede the 2019 EU parliamentary elections and the appointment of a new European Commission, acting as a bridge for national and regional priorities across policy areas such as clinical trials, data protection, genomics and the ongoing development and training of healthcare professionals.

Complimentary bonus! The first 350 Public Health Professionals can benefit from complimentary passes to the event in the Lombardy capital!

More info available here: http://eapmmilan2018.com/

Past events and updates

PRECeDI Open Seminar
"Policy development in Personalized Medicine".

The "Personalized pREvention of Chronic DIseases consortium (PRECeDI)" project updates:

The project "Personalized pREvention of Chronic DIseases consortium (PRECeDI)" is funded by the Marie Skłodowska-Curie EU programme, with the aim to provide high-quality, multidisciplinary knowledge through training and research in Personalized Medicine, with specific reference to prevention of chronic diseases. The project consortium consists of 11 partners, including EUPHA, and is coordinated by the Section of Hygiene-Institute of Public Health of the Catholic University of the Sacred Heart of Rome (Italy).

We are very pleased to report on a very interesting PRECeDI Open Seminar "Policy development in Personalized Medicine" which took place at the VU University, Amsterdam during March 2018. The seminar addressed some important issues, such as the promise of omics techniques in personalised medicine, prioritization and strategies for integrating personalized medicine in health care systems.
The audience was able to hear some state-of-the-art presentations from our key-speakers: **Cornelia Van Duijn** (Erasmus MC), **Vera Codazzi** (Assobiomedica), **Martina Cornel** (VUMC), **Ron Zimmern** (PHG Foundation), **Paolo Villari** (Sapienza University), **Walter Ricciardi** (ISS). The Round table provoked some meaningful discussions and covered the topic of fostering innovation in Personalised Medicine and the impact for the health systems. The international discussants were led by Anant Jani (BVHC) and are further listed: **Natasha Azzopardi Muscat** (EUPHA) , **Dick Willems** (AMC), **Martine de Bruijne** (VUMC), **Tessel Rigter** (VUMC), **Stefania Boccia** (UCSC), **Ma'n H. Zawati** (McGill), **Jim Roldan** (LinkCare), **Denis Horgan** (EAPM) and **Maurizio Genuardi** (UCSC- Italian Society of Human Genetics). Several photos from the event are outlined below and the event information will be soon available at the PRECeDI website (http://www.precedi.eu/site/):


Acting together
EXECUTIVE SUMMARY AND RECOMMENDATIONS


VUmc
Value Based Health Care
• Helps to improve health care
• Based on values agreed upon
➢ Personal value
➢ Autonomy, self management
➢ Technical value
➢ Excellent counseling
➢ Allocative value
➢ Shift resources? Optimal population impact for given budget


Life time risk of AD by age in the Rotterdam Study
Age of interest industry
AD is common
Mild Cognitive Impairment (MCI)
Early pathology MRI/PET
Age (years)


Policy issues
The implementation of any disruptive innovation, should carefully address the issues of relevance, equity (including access), quality, cost-effectiveness, person- and people centeredness, and sustainability.
Policy makers should analyse how to enhance the enablers and to address the already identified possible barriers for implementing a disruptive innovation within a health system.
When identifying the areas of introduction of a disruptive innovation, it is necessary to take into consideration the aspects regarding its:
Projected Impacts
Context
Feasibility


EUPHA
PRECeDI
L-Università ta' Malta
Public Health
Personalised Medicine
Change
Community
Individual
Cost containment
Innovation


Ickworth 2017
phg foundation
1. Necessity to take revolutionary disruptive leaps by radical reorientation of health systems necessary
1. Greater responsiveness to both ageing population and to epidemics
1. Greater emphasis on health and on disease prevention
4. Free the data
5. Engage the citizen
6. Break down silos
5. Actively develop leaders


INAPPROPRIATE USE vs CITIZENS' RIGHTS
GENETIC/GENOMIC APPLICATIONS SHOULD BE EVALUATED RIGOROUSLY BEFORE ENTERING INTO CLINICAL AND PUBLIC HEALTH PRACTICE
GENETIC/GENOMIC APPLICATIONS WITH PROVED EFFICACY AND COST-EFFECTIVENESS SHOULD BECOME CITIZENS'RIGHTS

The Innovative Partnership for Action Against Cancer (iPAAC) has officially started on 1 April 2018

iPAAC is funded under the Third Health Programme 2014–2020 and aims to build upon the outcomes of previous EPAAC and CANCON Joint Actions. iPAAC includes around 40 partners from 24 European countries and is coordinated by the National Institute of Public Health Slovenia (NIJZ).

The general aim of the iPAAC Joint Action is to develop innovative approaches to advance cancer control, including further development of cancer prevention, comprehensive approaches to the use of genomics in cancer control, cancer information and registries, improvements and challenges in cancer care, mapping of innovative cancer treatments and governance of integrated cancer control etc. The key focus of the Joint Action is on implementation, and the primary target group are EU-level policymakers and decision makers at national, regional and local levels.

More information, updates and news about the iPAAC Joint Action can be obtained by visiting the official website: https://www.ipaac.eu/

The first official meeting of the full Joint Action consortium took place in Luxembourg on 16–17 April 2018. More details available at:
https://www.ipaac.eu/news-detail/en/1-the-ipaac-project-launched-at-a-kick-off-meeting-in-luxembourg/

European Parliament Committee on the Environment, Public Health and Food Safety (ENVI) Workshop :
"Digitalisation and Big Data: Implications for the Health Sector"

This interesting workshop, held on Tuesday 19 June in Brussels. Belgium, aimed to analyse the implications of digitalisation and Big Data for the health sector. It consisted of different presentations by experts in the field and an exchange of views with EP Members and established external experts in the area, on some of the following topics:

Digitalisation in healthcare and the sources of Big Data; EU healthcare systems and the potential for Big Data; Clinical and cultural challenges ahead for efficient use of Big Data in healthcare; Technical challenges related to the management of electronic health records; Legal and regulatory aspects, including privacy protection and data sharing policies; Training and education.

Some information on this workshop can be found on the EP website:
http://www.europarl.europa.eu/committees/en/envi/events-workshops.html?id=20180621WKS01781

Scientific publications:

1. Djordjevic N, Boccia S, Ádány R. **Editorial: Translation of Genomic Results Into Public Health Practice.** Front Public Health. 2018 May 25;6:156. doi: 10.3389/fpubh.2018.00156. eCollection 2018.

2. Bíró K, Dombrádi V, Jani A, Boruzs K, Gray M. **Creating a common language: defining individualized, personalized and precision prevention in public health**. J Public Health (Oxf). 2018 Apr 20. doi: 10.1093/pubmed/fdy066.

3. Leoncini E, Vukovic V, Cadoni G, Giraldi L, Pastorino R, Arzani D, Petrelli L, Wünsch-Filho V, Toporcov TN, Moyses RA, Matsuo K, Bosetti C, La Vecchia C, Serraino D, Simonato L, Merletti F, Boffetta P, Hashibe M, Lee YA, Boccia S. **Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium.** Eur J Epidemiol. 2018 May 19. doi: 10.1007/s10654-018-0409-5.

4. Pastorino R, Puggina A, Carreras-Torres R, Lagiou P, Holcátová I, Richiardi L, Kjaerheim K, Agudo A, Castellsagué X, Macfarlane TV, Barzan L, Canova C, Thakker NS, Conway DI, Znaor A, Healy CM, Ahrens W, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Fabianova E, Mates IN, Bencko V, Foretova L, Janout V, Brennan P, Gaborieau V, McKay JD, Boccia S. **Genetic Contributions to The Association Between Adult Height and Head and Neck Cancer: A Mendelian Randomization Analysis.** Sci Rep. 2018 Mar 14;8(1):4534. doi: 10.1038/s41598-018-22626-w.

5. Rafiq M, Boccia S. **Application of the GRADE Approach in the Development of Guidelines and Recommendations in Genomic Medicine.** Genomics Insights. 2018 Jan 30;11:1178631017753360. doi: 10.1177/1178631017753360. eCollection 2018.

6. Di Marco M, D'Andrea E, Panic N, Baccolini V, Migliara G, Marzuillo C, De Vito C, Pastorino R, Boccia S, Villari P. **Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations.** Genet Med. 2018 Jan 4. doi: 10.1038/gim.2017.244.

7. Liu J, van Klinken JB, Semiz S, van Dijk KW5, Verhoeven A, Hankemeier T, Harms AC, Sijbrands E, Sheehan NA, van Duijn CM, Demirkan A. **A Mendelian Randomization Study of Metabolite Profiles, Fasting Glucose, and Type 2 Diabetes.** Diabetes. 2017 Nov;66(11):2915-2926. doi: 10.2337/db17-0199. Epub 2017 Aug 28.

8. Colace L, Boccia S, De Maria R, Zeuner A. **Colorectal cancer: towards new challenges and concepts of preventive healthcare.** Ecancermedicalscience. 2017 Nov 28;11:ed74. doi: 10.3332/ecancer.2017.ed74. eCollection 2017.

9. De Felice F, Marchetti C, Boccia SM, Romito A, Sassu CM, Porpora MG, Muzii L, Tombolini V, Benedetti Panici P. **Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know.** Cancer Treat Rev. 2017 Dec;61:1-5. doi: 10.1016/j.ctrv.2017.09.005. Epub 2017 Sep 28.

10. Gyulai A, Nagy A, Pataki V, Tonté D, Ádány R, Vokó Z. **General practitioners can increase participation in cervical cancer screening - a model program in Hungary.** BMC Fam Pract. 2018 May 19;19(1):67. doi: 10.1186/s12875-018-0755-0.

11. Fiatal S, Ádány R. **Application of Single-Nucleotide Polymorphism-Related Risk Estimates in Identification of Increased Genetic Susceptibility to Cardiovascular Diseases: A Literature Review.** Front Public Health. 2018 Jan 31;5:358. doi: 10.3389/fpubh.2017.00358. eCollection 2017.

12. Nagy K, Fiatal S, Sándor J, Ádány R. **Distinct Penetrance of Obesity-Associated Susceptibility**

Alleles in the Hungarian General and Roma Populations. Obes Facts. 2017;10(5):444-457. doi: 10.1159/000478094. Epub 2017 Oct 7.

13. Friedman JM, Bombard Y, Cornel MC, Fernandez CV, Junker AK, Plon SE, Stark Z, Knoppers BM; **Paediatric Task Team of the Global Alliance for Genomics and Health Regulatory and Ethics Work Stream. Genome-wide sequencing in acutely ill infants: genomic medicine's critical application?** Genet Med. 2018 Jun 12. doi: 10.1038/s41436-018-0055-z.

14. Rahimzadeh V, Schickhardt C, Knoppers BM, Sénécal K, Vears DF, Fernandez CV, Pfister S, Plon S, Terry S, Williams J, Williams MS, Cornel M, Friedman JM. **Key Implications of Data Sharing in Pediatric Genomics.** JAMA Pediatr. 2018 May 1;172(5):476-481. doi: 10.1001/jamapediatrics.2017.5500.

15. Sirchia F, Carrieri D, Dheensa S, Benjamin C, Kayserili H, Cordier C, van El CG, Turnpenny PD, Melegh B, Mendes Á, Halbersma-Konings TF, van Langen IM, Lucassen AM, Clarke AJ, Forzano F, Kelly SE. **Recontacting or not recontacting? A survey of current practices in clinical genetics centres in Europe.** Eur J Hum Genet. 2018 Jul;26(7):946-954. doi: 10.1038/s41431-018-0131-5. Epub 2018 Apr 23.

16. van der Lee SJ, Wolters FJ, Ikram MK, Hofman A, Ikram MA, Amin N, van Duijn CM. **The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study.** Lancet Neurol. 2018 May;17(5):434-444. doi: 10.1016/S1474-4422(18)30053-X. Epub 2018 Mar 16.

17. Di Marco M, D'Andrea E, Villari P. **Universal screening of Lynch syndrome is ready for implementation.** Genet Med. 2018 May 8. doi: 10.1038/s41436-018-0027-3.

18. Pitini E, De Vito C, Marzuillo C, D'Andrea E, Rosso A, Federici A, Di Maria E, Villari P. **How is genetic testing evaluated? A systematic review of the literature.** Eur J Hum Genet. 2018 May;26(5):605-615. doi: 10.1038/s41431-018-0095-5. Epub 2018 Feb 8.

19. D'Andrea E, Lagerberg T, De Vito C, Pitini E, Marzuillo C, Massimi A, Vacchio MR, Grammatico P, Villari P. **Patient experience and utility of genetic information: a cross-sectional study among patients tested for cancer susceptibility and thrombophilia.** Eur J Hum Genet. 2018 Apr;26(4):518-526. doi: 10.1038/s41431-017-0083-1. Epub 2018 Jan 26.

Please contact our Section, if you have some further information and think that it might be interesting for other members to know (*upcoming international courses, lectures and conferences from the field, international projects to participate – call for application, networking opportunities, possible job application within your institution interesting for our members, scientific publications, etc.*).

Warm greetings and see you in Ljubljana!

Róza Ádány and Stefania Boccia